OPKO Health, Inc. (OPK) is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE's performance and strategic partnerships. However, stiff competition and overdependence on RAYALDEE are concerns. Shares of this Zacks Rank #3 (Hold) company have lost 1.3% year to date against the industry's 9.8% growth. The S&P 500 has gained 21% in the said time frame. This renowned multinational biopharmaceutical and diagnostics company ...

OPKO Health, Inc. (OPK) delivered a loss per share of a penny in the second quarter of 2024, narrower than the year-ago period's loss of 3 cents per share and the Zacks Consensus Estimate of a loss of 9 cents per share. Revenues in Detail OPKO Health registered revenues of $182.2 million in the second quarter, down 31.3% year over year. The figure, however, missed the Zacks Consensus Estimate by 1.7%. Lower revenues from products and transfer of intellectual property and other dragged the overall top line. ...

OPKO Health (OPK) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 88.89%. A quarter ago, it was expected that this holding company with investments in pharmaceutical and diagnostics companies would post a loss of $0.09 per share when it actually produced a loss of $0.12, delivering a surpris ...

OPKO Health, Inc. (NASDAQ:OPK) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Yvonne Briggs – LHA Investor Relations Phillip Frost – Chairman and Chief Executive Officer Elias Zerhouni – Vice Chairman and President Adam Logal – Chief Financial Officer Conference Call Participants Maury Raycroft – Jefferies Yale Jen – Laidlaw and Company Michael Petusky – Barrington Research Operator Good day, and welcome to the OPKO Health Second Quarter 2024 Financial Results Conference Cal ...

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common stock from time to time through open market purchases, block trades, privately negotiated transactions, accelerated share repurchase transactions and/or pursuant to Rule 10b5-1 plans, in compliance with applicable securities laws an ...

Company Overview - OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company focused on establishing industry-leading positions in rapidly growing markets through its discovery, development, and commercialization expertise [4] - The company is currently marketing NGENLA™, a once-weekly treatment for pediatric growth hormone deficiency [1] Financial Transaction - OPKO has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx), secured by profit share payments from Pfizer related to NGENLA™ [1][2] - The note bears interest at the 3-month Secured Overnight Financing Rate (SOFR) with a 4.0% per annum floor, plus 7.5% per annum, and has a final maturity date of July 2044 [2] - The first four years of the note require interest-only payments, allowing OPKO to retain a significant portion of NGENLA's profit share payments in the near term [2] Strategic Implications - The transaction provides OPKO with non-dilutive capital and financial flexibility to advance research and development activities, including multispecific antibody programs, and potentially repurchase shares and convertible notes [2] - OPKO retains the full benefit of $100 million in remaining potential milestone payments from Pfizer, enhancing its long-term financial outlook [2] HealthCare Royalty Overview - HealthCare Royalty is a leading royalty acquisition company that has invested over $5 billion in more than 85 biopharmaceutical products since its inception [3] - The company focuses on commercial or near-commercial biopharmaceutical products, indicating a strong market presence and expertise in the sector [3]

It has been about a month since the last earnings report for OPKO Health (OPK) . Shares have added about 12.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is OPKO Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. OPKO Health's Q1 Earnings Miss Estimates, Sale ...

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com. Contacts: LHA Investor Relations Yvonne Briggs, 310-691-7100 ybriggs@lhai.com or Bruce Voss, 310-691-7100 bvoss@lhai.com MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced tod ...

OPKO Health, Inc. (OPK) delivered a loss per share of 12 cents in the first quarter of 2024, wider than the year-ago period’s loss of 2 cents per share. The figure missed the Zacks Consensus Estimate of a loss of 9 cents per share by 33.3%.Revenues in DetailOPKO Health registered sales of $173.7 million, down 26.9% year over year. The figure missed the Zacks Consensus Estimate by 5%.Lower revenues from the transfer of intellectual property and others dragged the overall top line.Segmental RevenuesOPKO Healt ...

For the quarter ended March 2024, OPKO Health (OPK) reported revenue of $173.7 million, down 26.9% over the same period last year. EPS came in at -$0.12, compared to -$0.02 in the year-ago quarter.The reported revenue represents a surprise of -5.00% over the Zacks Consensus Estimate of $182.84 million. With the consensus EPS estimate being -$0.09, the EPS surprise was -33.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...